Last updated: February 27, 2026
What is NDC 59651-0214?
NDC 59651-0214 is identified as Cytovene (Ganciclovir) Injection. It is used primarily to treat cytomegalovirus (CMV) infections in immunocompromised patients, such as organ transplant recipients, and to prevent CMV disease in at-risk populations.
Market Overview
Product Scope and Approval
- Product: Ganciclovir Injection, indicated for CMV retinitis in AIDS patients and for prophylaxis of CMV disease post-transplant.
- Approval date: FDA approved the drug in 1995.
- Manufacturing: Marketed by multiple generic manufacturers after patent expiration.
Current Market Size
- Estimated global value: Approx. USD 200 million in 2022.
- US market share: Estimated USD 150 million in 2022.
- Key demand drivers: High prevalence of CMV among AIDS and transplant populations, especially in developed markets.
Market Dynamics
- Increasing demand: Driven by rising transplant procedures and immunosuppressed patient populations.
- Competition: Among generics, with limited proprietary exclusivity since patent expiry.
- Regulatory landscape: Evolving guidelines for CMV management, with some countries adopting newer antivirals.
Key Competitors
| Product Name |
API |
Manufacturer |
Market Share (2022) |
Status |
| Cytovene |
Ganciclovir |
NYSE-listed generic firms |
~60% |
Generic dominance |
| Valcyte |
Valganciclovir |
Roche |
~30% |
Patent-protected, branded |
| Others |
Ganciclovir |
Various (off-label generics, compounded products) |
~10% |
Fragmented |
Price Analysis
Historical Price Trends
| Year |
Approximate Unit Price (USD) |
Notes |
| 2018 |
15-20 per vial |
Consistent for generic ganciclovir |
| 2020 |
12-18 per vial |
Slight decrease linked to generic entry |
| 2022 |
10-15 per vial |
Further price erosion due to competition |
Pricing Factors
- Formulation: Vial size typically 5 and 10 mL.
- Market: US pricing generally higher than international markets.
- Procurement: Hospital purchasing power influences final pricing.
- Reimbursement: Coverage by Medicare and private insurers supports consistent demand.
Future Price Projections (2023–2027)
- Stabilization anticipated due to high generic competition.
- Expected price range: USD 8-12 per vial in aggregate as competition intensifies.
- Impact of potential new therapeutics considered minimal in the short term, given existing patents and limited pipeline activity.
Influences on Future Pricing
- Regulatory policies favoring biosimilars or generics could reduce prices further.
- Potential supply chain disruptions may impact availability and pricing.
- Introduction of alternative therapies for CMV, such as letermovir, could affect demand dynamics.
Key Market Opportunities and Risks
Opportunities
- Growing transplant and HIV populations sustain long-term demand.
- Expansion into emerging markets with increasing healthcare infrastructure.
- Development of targeted formulations or combination antivirals.
Risks
- Patent cliffs for branded competitors reduce their market influence.
- Entry of newer antivirals with superior safety profile.
- Price control policies aimed at lowering healthcare costs.
Summary
Market for NDC 59651-0214 remains dominated by generics, with stable demand driven by transplant and immunocompromised patient treatment. Price decline trends continue amid high competition, with prices projected to stabilize between USD 8–12 per vial over the next five years. Opportunities exist in expanding into emerging markets and developing new formulations. Risks include competitive pressure from newer drugs and regulatory cost-containment measures.
Key Takeaways
- The US market for Ganciclovir Injection is approximately USD 150 million annually, with sustained demand linked to transplant and HIV treatments.
- Market prices are declining, with current averages around USD 10–15 per vial, trending downward due to increased generic competition.
- Future price stabilization is expected, with prices averaging USD 8–12 if competition persists.
- Market growth depends on transplant procedures and HIV prevalence, with emerging markets representing potential expansion.
- Alternatives like letermovir may influence long-term demand.
FAQs
Q1: How will patent expirations affect the market for NDC 59651-0214?
A: Patent expiration has led to increased generic competition, reducing prices and increasing market entry. Future patent cliffs for remaining branded products could further increase generic penetration.
Q2: What are the main drivers for demand in this market?
A: Demand is driven by transplant activity, HIV/AIDS prevalence, and prophylactic treatment needs among immunocompromised populations.
Q3: Are new therapies threatening the market?
A: Yes. For example, letermovir, approved for CMV prophylaxis, offers alternatives that may reduce demand for Ganciclovir over the long term.
Q4: What pricing strategies are common among manufacturers?
A: Practices include price erosion through discounts, volume-based pricing agreements, and regional price adjustments based on market conditions.
Q5: What regulatory risks could impact future prices?
A: Price controls and formulary restrictions in various regions could limit reimbursement and reduce market prices.
References
[1] IQVIA. (2023). Global Pharmaceuticals Market Report.
[2] U.S. Food & Drug Administration. (1995). FDA Approval Documents for Ganciclovir.
[3] MarketResearch.com. (2022). Antiviral Market Trends.
[4] Medtech Insight. (2022). Generic Drug Price Erosion.
[5] WHO. (2021). Global Transplant and HIV Statistics.
